The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
It’s a new term for biotech and its investors.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
The same trial that sent Summit up 272% sees the stock crash 36%.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.